| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Lipid peroxidation / Ferroptosis axis |
↑ (pro-ferroptotic bias; dose-dependent) |
↔ / mild ↑ (buffered) |
P→R |
PUFA enrichment → lipid-ROS susceptibility |
DHA increases membrane PUFA content; tumors with weak GPX4 defenses more vulnerable (model-dependent). |
| 2 |
ROS tone |
↑ (high concentration only) |
↔ |
P→R |
Oxidative stress induction |
Free DHA oxidation can elevate ROS in cancer; physiologic dosing less pronounced. |
| 3 |
Inflammation (NF-κB / COX-2) |
↓ |
↓ |
R→G |
Anti-inflammatory / pro-resolving |
Via resolvins/protectins; may reduce tumor-promoting inflammation. |
| 4 |
Membrane signaling / lipid rafts |
↓ oncogenic signaling (context-dependent) |
Modulates receptor clustering |
R→G |
Alters RTK / Akt pathway localization |
Changes raft composition; can dampen EGFR/PI3K signaling (model-dependent). |
| 5 |
HIF-1α / hypoxia signaling |
↓ (model-dependent) |
↔ |
G |
Reduced hypoxic adaptation |
Reported in some solid tumor models; not universal. |
| 6 |
NRF2 axis |
↔ / ↑ (adaptive) |
↑ (protective) |
G |
Antioxidant adaptation |
Lipid peroxidation may secondarily activate NRF2; can limit ferroptosis in resistant tumors. |
| 7 |
Ca²⁺ signaling / ER stress |
↑ (high concentration only) |
↔ |
R |
Stress-induced apoptosis (select models) |
High free DHA can perturb ER Ca²⁺ handling; typically supra-physiologic exposure. |
| 8 |
Clinical Translation Constraint |
— |
— |
— |
Adjunct potential |
In-vitro dosing often exceeds systemic free DHA; best studied as chemo-sensitizing adjunct rather than monotherapy. |
| Rank |
Pathway / Axis |
Cells (neurons/glia) |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Membrane fluidity / synaptic integrity |
↑ |
G |
Synaptic stabilization |
DHA major neuronal phospholipid; supports dendritic spine density and neurotransmission. |
| 2 |
Neuroinflammation resolution |
↓ (pro-resolving) |
R→G |
Resolvins / protectins |
Promotes resolution rather than suppression of inflammation; relevant in microglial activation. |
| 3 |
Mitochondrial efficiency |
↑ (stabilizing) |
R→G |
Bioenergetic support |
Improves membrane dynamics of mitochondria; may enhance ATP coupling (model-dependent). |
| 4 |
Aβ processing / amyloid burden |
↓ (preclinical) |
G |
Modulates APP cleavage |
Animal/cell data supportive; human trials mixed, stronger in early/MCI stages. |
| 5 |
BDNF / neuroplasticity |
↑ (model-dependent) |
G |
Neurotrophic support |
Reported increase in BDNF signaling in experimental models. |
| 6 |
Clinical Translation Constraint |
— |
— |
Stage-dependent benefit |
MCI/early AD may benefit; established AD shows limited cognitive reversal in RCTs; incorporation requires sustained intake. |